FL 115
Alternative Names: FL-115Latest Information Update: 08 Dec 2023
At a glance
- Originator Suzhou Forlong Biotechnology
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Oct 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT06130722)